Lapatinib plus Letrozole as First-Line Therapy for HER-2(+) Hormone Receptor–Positive Metastatic Breast Cancer

Documenti analoghi

• Lapatinib plus Letrozole as First-Line Therapy for HER-2(+) Hormone Receptor–Positive Metastatic Breast Cancer
  di: Schwartzberg, Lee S., et al.
  Pubblicazione: (2010)
• Quality of Life in Hormone Receptor–Positive HER-2(+) Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib
  di: Sherrill, Beth, et al.
  Pubblicazione: (2010)
• An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
  di: Esteva, Francisco J., et al.
  Pubblicazione: (2013)
• Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor-and HER2-Positive Metastatic Breast Cancer
  di: Delea, Thomas E., et al.
  Pubblicazione: (2013)
• Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor–positive metastatic breast cancer in Canada
  di: Delea, T.E., et al.
  Pubblicazione: (2013)